Abstract Library

#4660 Clinical significance of interval imaging in patients with well-differentiated neuroendocrine neoplasms (NENs) receiving peptide receptor radionuclide therapy (PRRT)

Introduction: PRRT is an effective therapy for advanced NENs with SSTR-avid disease, however, the role of interval imaging in between PRRT cycles and its benefit is unknown.

Conference:

Presenting Author:

Authors: Grewal U, Patel R, Chandasekharan C,

Keywords: Peptide receptor radionuclide therapy, interval imaging, neuroendocrine tumour,

#4584 Hepatic cytoreduction in advanced lung neuroendocrine neoplasms: A single institutional case series

Introduction: Role of hepatic cytoreductive surgery in well-differentiated gastroenteropancreatic neuroendocrine neoplasms (NENs) with liver metastases is well-described, however, its role in advanced lung NENs with liver metastases is unknown.

Conference:

Presenting Author: Grewal U

Authors: Grewal U, Patel R, Furqan M, Dillon J, Chandasekharan C,

Keywords: Lung neuroendocrine neoplasm, Hepatic cytoreductive surgery,

#4569 Dramatic response to tarlatamab in a patient with metastatic primary small cell neuroendocrine carcinoma of the breast

Introduction: Primary small cell neuroendocrine carcinoma of the breast (SCNCB) is a rare malignancy with a poor prognosis. Tarlatamab, a DLL3-targeted bispecific T-cell engager, is FDA-approved for extensive-stage small cell lung carcinoma.

Conference:

Presenting Author: Patel D

Authors: Patel D, Alahmadi A, Maddocks K, Lampert B, Giglio P,

Keywords: tarlatamab, small cell neuroendocrine carcinoma of the breast,

#4463 Evaluating multi-visceral resection for locally advanced and metastatic pancreatic neuroendocrine tumours (PNETs): Feasibility, safety and complications

Introduction: Pancreatic neuroendocrine tumours (PNETs) are rare but clinically significant neoplasms. Surgery can play a significant role in the multimodal treatment of PNETs. Multi-visceral resection involving organs in the left upper quadrant (LUQ) can be used with curative or cytoreductive intent in selected cases.

Conference:

Presenting Author:

Authors: Ee J, Patel R, Hamady Z, Pike T, Karavias D,

Keywords: neuroendocrine, tumour, pancreatic, multivisceral,

#2776 The Effects of Somatostatin Analogues on HbA1c and BMI in the Treatment of Neuroendocrine Tumours

Introduction: Long acting somatostatin analogues (SSA) are the most commonly used drugs in the management of neuroendocrine tumours (NETs) due to their ability to control symptoms and prolong survival. SSAs use is associated with changes in glucose metabolism. However, there is lack of data for such effects in patients with NETs. We evaluated the effects of SSA on BMI and HbA1c in our cohort of patients with NETs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Patel K

Authors: Patel K, Nahar A, Elhassan Y, Shah T, Ayuk J,

Keywords: Somatostatin analogues, Diabetes, Neuroendocrine tumour, HbA1c, BMI,